Scientists hunt for safe dose in new brain cancer drug combo
NCT ID NCT06095375
Summary
This early-stage study tested adding a drug called regorafenib to the standard treatment for a fast-growing brain cancer called glioblastoma. The main goal was to find the highest dose of regorafenib that patients could safely take alongside their usual chemotherapy and radiation. The study involved 21 adults with a specific type of glioblastoma to see if this combination could help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanitas Research Hospital
Rozzano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, 35128, Italy
Conditions
Explore the condition pages connected to this study.